Focused chemistry from annotated libraries

Drug Discovery Today: Technologies

Volumn 3, Issue 4, 2006, Pages 397-403

  Balakin, Konstantin V ^a   Tkachenko, Sergey E ^a   Kiselyov, Alexander S ^a   Savchuk, Nikolay P ^a  

^a CHEMDIV INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; G PROTEIN COUPLED RECEPTOR; HORMONE RECEPTOR; ION CHANNEL; PHOSPHODIESTERASE; PROTEIN KINASE; PROTEINASE;

BIOINFORMATICS; COMBINATORIAL CHEMISTRY; COMBINATORIAL LIBRARY; COMPUTER MODEL; COMPUTER PROGRAM; CRYSTALLOGRAPHY; DATA MINING; DRUG ACTIVITY; DRUG INFORMATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; GENE EXPRESSION PROFILING; HIGH THROUGHPUT SCREENING; INFORMATION PROCESSING; INTERNET; KNOWLEDGE BASE; PROCESS TECHNOLOGY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REFERENCE DATABASE; REVIEW; STRUCTURE ACTIVITY RELATION; TOXICOGENETICS;

EID: 33846498431     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2006.12.006     Document Type: Review

References (31)

1. Weinstein J.N., et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275 (1997) 343-349
2. Mestres J. Computational chemogenomics approaches to systematic knowledge-based drug discovery. Curr. Opin. Drug Discov. Dev. 7 (2004) 304-313
3. Bredel M., and Jacoby E. Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat. Rev. Genet. 5 (2004) 262-275
4. Savchuk N.P., et al. Exploring the chemogenomic knowledge space with annotated chemical libraries. Curr. Opin. Chem. Biol. 8 (2004) 412-417
5. Blower P.E., et al. Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data. Pharmacogenomics J. 2 (2002) 259-271
6. Rabow A.A., et al. Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. J. Med. Chem. 45 (2002) 818-840
7. Wallqvist A., et al. Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology. Mol. Cancer Therap. 1 (2002) 311-320
8. Rickardson L., et al. Screening of an annotated compound library for drug activity in a resistant myeloma cell line. Cancer Chemother. Pharmacol. 58 (2006) 749-758
9. Root D.E., et al. Biological mechanism profiling using an annotated compound library. Chem. Biol. 10 (2003) 881-892
10. Klekota J., et al. Using high-throughput screening data to discriminate compounds with single-target effects from those with side effects. J. Chem. Inf. Model. 46 (2006) 1549-1562
11. Frye S.V. Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. Chem. Biol. 6 (1999) R3-R7
12. Schuffenhauer A., et al. An ontology for pharmaceutical ligands and its application for in silico screening and library design. J. Chem. Inf. Comput. Sci. 42 (2002) 947-955
13. Schuffenhauer A., et al. Similarity metrics for ligands reflecting the similarity of the target proteins. J. Chem. Inf. Comp. Sci. 43 (2003) 391-405
14. Greenbaum D.C., et al. Small molecule affinity fingerprinting. A tool for enzyme family subclassification, target identification, and inhibitor design. Chem. Biol. 9 (2002) 1085-1094
15. Vieth M., et al. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys. Acta 1697 (2004) 243-257
16. Fabian M.A., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23 (2005) 329-336
17. Cases M., et al. Chemical and biological profiling of an annotated compound library directed to the nuclear receptor family. Curr. Top. Med. Chem. 5 (2005) 763-772
18. Janzen W.P., and Hodge C.N. A chemogenomic approach to discovering target-selective drugs. Chem. Biol. Drug Des. 76 (2006) 85-86
19. Lagunin A., et al. PASS: prediction of activity spectra for biologically active substances. Bioinformatics 16 (2000) 747-748
20. Poroikov V., et al. Top 200 medicines: can new actions be discovered through computer-aided prediction?. SAR QSAR Environ. Res. 12 (2001) 327-344
21. Balakin K.V., et al. Comprehensive computational assessment of ADME properties using mapping techniques. Curr. Drug Discov. Technol. 2 (2005) 99-113
22. Krejsa C.M., et al. Predicting ADME properties and side effects: the BioPrint approach. Curr. Opin. Drug Discov. Dev. 6 (2003) 470-480
23. Ganter B., et al. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J. Biotechnol. 119 (2005) 219-244
24. Horvath D., and Jeandenans C. Neighborhood behavior of in silico structural spaces with respect to in vitro activity spaces-a novel understanding of the molecular similarity principle in the context of multiple receptor binding profiles. J. Chem. Inf. Comput. Sci. 43 (2003) 680-690
25. Rolland C., et al. G-protein-coupled receptor affinity prediction based on the use of a profiling dataset: QSAR design, synthesis, and experimental validation. J. Med. Chem. 48 (2005) 6563-6574
26. Engelberg A. Iconix Pharmaceuticals, Inc.-removing barriers to efficient drug discovery through chemogenomics. Pharmacogenomics 5 (2004) 741-744
27. Olah M., et al. WOMBAT: World of Molecular Bioactivity. In: Oprea T.I. (Ed). Cheminformatics in Drug Discovery (2004), Wiley-VCH 223-239
28. Olah M., et al. An automated PLS search for biologically relevant QSAR descriptors. J. Comp.-Aid. Mol. Des. 18 (2004) 437-449
29. Nidhi, et al. Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J. Chem. Inf. Model. 46 (2006) 1124-1133
30. Dubus E., et al. In silico classification of hERG channel blockers: a knowledge-based strategy. Chem. Med. Chem. 1 (2006) 622-630
31. Schurer S.C., et al. Prospective exploration of synthetically feasible, medicinally relevant chemical space. J. Chem. Inf. Model. 45 (2005) 239-248